Piper Sandler lowered the firm’s price target on Moderna (MRNA) to $63 from $69 and keeps an Overweight rating on the shares. The firm notes Moderna laid out growth plans driven by mNEXSPIKE in 2026; mRNA-1010, intismeran and European growth in 2027; and mRNA-1083 and mRNA-1403 in 2028. Piper projects product sales of $1.73B in 2025 to grow to $2.15B in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Cautious Hold on Moderna Amid Strategic Pipeline Shift and Financial Uncertainty
- Moderna’s Strategic Growth and Financial Outlook: Buy Rating Affirmed by Analyst David Dai
- Moderna’s Ambitious Growth Plans and Financial Complexities Lead to Hold Rating
- Moderna’s Strategic Shift and Financial Outlook: A Hold Rating Amid Cautious Optimism
- Cautious Outlook on Moderna: Hold Rating Amid Breakeven Challenges and Pipeline Prospects